(4-hydroxycyclohexyl) acetate | 68592-22-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-hydroxycyclohexyl) acetate
• 英文别名: cis-(4-hydroxy-cyclohexyl)-acetic acid；cis-(4-Hydroxy-cyclohexyl)-essigsaeure；(cis-4-hydroxycyclohexyl)acetic acid；cis-<4-Hydroxy-cyclohexyl>-essigsaeure
• CAS: 68592-22-3
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: ALTAAUJNHYWOGS-KNVOCYPGSA-N

物化性质

• 熔点：
  133.5-134 °C
• 沸点：
  326.4±15.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.01
• 重原子数：
  11.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  57.53
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (4-hydroxycyclohexyl) acetate 、 1,4-二氧杂螺[4.5]癸-7-烯-8-基三氟甲磺酸酯 在 [Ir(dF(CF₃)ppy)₂(dtbbpy)](PF₆) 、 nickel(II)-4,4'-di(tert-butyl-2,2'-bipyridine) bromide 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以65 %的产率得到
  参考文献：
  名称：

  克服烷基羧酸与烯醇三氟甲磺酸酯之间金属光氧化还原催化脱羧烯基化的能量转移

  摘要：

  克服金属光氧化还原催化的烷基羧酸和烯醇三氟甲磺酸酯之间的脱羧烯基化的能量转移。

  DOI：

  10.1002/chem.202300265
• 作为产物：
  描述：

  2-(4-氧代环己基)乙酸 在 sodium hydroxide 、 镍 作用下， 生成 (4-hydroxycyclohexyl) acetate
  参考文献：
  名称：

  酚酸的氢化。

  摘要：

  DOI：

  10.1021/ja01185a070

文献信息

• [EN] COMPOUNDS AS DGAT-1 INHIBITORS<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE DGAT-1
  申请人：MERCK SHARP & DOHME

  公开号：WO2013096093A1

  公开（公告）日：2013-06-27

  Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本发明描述了公式I的化合物。公式I的化合物作为DGAT1抑制剂，可用于预防、治疗或作为治疗高脂血症、糖尿病和肥胖的药物。
• [EN] CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190<br/>[FR] COMPOSÉS CARBAMOYLES COMME INHIBITEURS DE DGAT1 190
  申请人：ASTRAZENECA AB

  公开号：WO2009081195A1

  公开（公告）日：2009-07-02

  DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

  DGAT-1抑制剂化合物公式(I)，药用可接受的盐和前药，以及药物组合物、制造它们的过程以及它们在治疗例如肥胖症中的用途，其中，例如，环A是可选取代的2,6-吡嗪二基；X是=O；环B是可选取代的1,4-苯基；Y1是直接键或-O-；Y2是-(CH2)r-，其中r是2或3；n是0或当Y1是环B和环C之间的直接键并且当环B是1,4-苯基和环C是(4-6C)环烷时，n是1；环C是可选取代的(4-6C)环烷、(7-10C)双环烷、(8-12C)三环烷、苯基或吡啶二基；L是直接键或-O-；p是0、1或2，并且当p是1或2时，RA1和RA2各自独立地为氢或(1-4C)烷基；Z是羧酸或其模拟物或生物等排体。
• BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090042943A1

  公开（公告）日：2009-02-12

  The present invention relates to compounds of formula (I) wherein R 1 and A are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D 3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT 2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及以下式（I）的化合物 其中R 1 和A如说明书中定义的作为血清素5-HT 2a 和多巴胺D 3 受体的双调节剂，它们的制备，含有它们的药物组合物以及它们作为药物的用途。一般式（I）的化合物对多巴胺D 3 和血清素（5-羟色胺；5-HT）5-HT 2A 受体具有高亲和力，并且在治疗精神分裂症等疾病以及抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍等其他疾病中具有有效性。
• [EN] IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE
  申请人：INTERVET INT BV

  公开号：WO2012164071A1

  公开（公告）日：2012-12-06

  Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了式(I)的化合物。式(I)的化合物作为DGAT1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• Xanthene and thioxanthene derivatives
  申请人：Kefalas A/S

  公开号：US04275209A1

  公开（公告）日：1981-06-23

  The present invention relates to novel thioxanthene and xanthene derivatives which have useful pharmacodynamic activity, such as neuroleptic activity and antiemetic activity, methods for the preparation of said derivatives, pharmaceutical compositions containing same, and a method for the treatment of psychic disorders by administering a therapeutically active amount of one of said derivatives to a living animal body, including human beings. The new compounds of the present invention corresponds to the Formula I: ##STR1## wherein X is a halogen atom, an alkyl group with from one to four carbon atoms inclusive, an alkyloxy group with from one to four carbon atoms inclusive, a methylthio group, a methylsulphonyl group, a dimethylsulfamoyl group, a trifluoromethyl group or an acetyl group; Y is hydrogen, fluorine or a methyl group; Z is oxygen or sulphur; n is an integer from zero to three inclusive, and R is a cycloalkyl group with from four to six carbon atoms inclusive in the ring substituted with from one to four substituents selected from optionally esterified hydroxy- or hydroxymethyl groups, methyl groups, amino groups, acetamido groups, mesylamino groups or oxo groups, a five- or six-membered saturated heterocyclic ring having one or two heteroatoms selected from oxygen and nitrogen atoms and being optionally substituted with an optionally esterified hydroxy group or oxo group, any esterified hydroxy group present being an ester of an aliphatic carboxylic acid having from ten to twentytwo carbon atoms inclusive, as well as their non-toxic pharmaceutically acceptable acid addition salts.

  本发明涉及新型噻吖喃和黄嘌呤衍生物，具有有用的药理活性，例如神经阻滞活性和抗恶心活性，制备上述衍生物的方法，含有它们的制药组合物，以及通过向生物体，包括人类，中注射一种所述衍生物的治疗有效量的方法治疗精神障碍。本发明的新化合物对应于公式I：##STR1##其中X是卤素原子，具有从1到4个碳原子的包括的烷基，具有从1到4个碳原子的包括的烷氧基，甲基硫基，甲基磺酰基，二甲基磺酰胺基，三氟甲基或乙酰基；Y是氢，氟或甲基；Z是氧或硫；n是从零到三的整数，R是在环中具有从一个到四个选自可选酯化羟基或羟甲基基团，甲基基团，氨基，乙酰胺基，甲磺胺基或氧基团的取代基的四到六个碳原子的环烷基，具有选自氧原子和氮原子的一个或两个杂原子的五-或六元饱和杂环，可选择地取代具有可选酯化羟基或氧基团的任何酯化羟基，存在的任何酯化羟基是具有从十到二十二个碳原子的脂肪族羧酸的酯，以及它们的非毒性药学上可接受的酸盐。